X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ivosidenib (24) 24
enasidenib (14) 14
acute myeloid leukemia (12) 12
acute myeloid-leukemia (9) 9
index medicus (9) 9
oncology (7) 7
venetoclax (7) 7
aml (6) 6
hematology (6) 6
isocitrate dehydrogenase (6) 6
leukemia (6) 6
mutation (6) 6
midostaurin (5) 5
mutations (5) 5
pharmacokinetics (5) 5
pharmacology & pharmacy (5) 5
prognostic-significance (5) 5
ag-120 (4) 4
cancer (4) 4
chemotherapy (4) 4
dehydrogenases (4) 4
gemtuzumab ozogamicin (4) 4
idh1 (4) 4
oncometabolite 2-hydroxyglutarate (4) 4
review (4) 4
adult patients (3) 3
ag-221 (3) 3
cpx-351 (3) 3
flt3 (3) 3
glioma (3) 3
humans (3) 3
idh (3) 3
lc-ms/ms (3) 3
medical prognosis (3) 3
metabolism (3) 3
method validation (3) 3
mutant idh1 (3) 3
refractory (3) 3
acute promyelocytic leukemia (2) 2
anthracyclines (2) 2
article (2) 2
bioavailability (2) 2
cancer therapies (2) 2
cells (2) 2
cholangiocarcinoma (2) 2
disease progression (2) 2
drug approval (2) 2
drug therapy (2) 2
epigenetics (2) 2
gemtuzumab (2) 2
gilteritinib (2) 2
glasdegib (2) 2
idh1 mutation (2) 2
idh2 mutations (2) 2
induction (2) 2
inhibition (2) 2
isocitrate dehydrogenase - antagonists & inhibitors (2) 2
isocitrate dehydrogenase 1 (2) 2
kinase inhibitor (2) 2
leukemia, myeloid, acute - drug therapy (2) 2
leukemia, myeloid, acute - genetics (2) 2
lymphomas (2) 2
mice plasma (2) 2
mutant idh2 (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
patients (2) 2
pharmacology (2) 2
pharmacology/toxicology (2) 2
relapsed (2) 2
research (2) 2
studies (2) 2
-2-hydroxyglutarate (1) 1
2-hydroxyglutarate (1) 1
absorption (1) 1
abt-199 (1) 1
activating mutation (1) 1
acute myelogenous leukemia (1) 1
acute myeloid leukemia aml (1) 1
acute myeloid leukemia, aml (1) 1
alleles (1) 1
allosteric properties (1) 1
allosteric site - drug effects (1) 1
allosteric site - genetics (1) 1
aminoglycosides - therapeutic use (1) 1
aminopyridines - chemistry (1) 1
aminopyridines - pharmacology (1) 1
aminopyridines - therapeutic use (1) 1
animals (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
apoptosis (1) 1
azacitidine (1) 1
bcl-2 family-members (1) 1
bcl-2 protein (1) 1
beta-hydroxyglutarate (1) 1
biochemical research methods (1) 1
biochemistry & molecular biology (1) 1
biological products (1) 1
biomedicine (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S7 - S9
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2019, Volume 32, Issue 4, p. 101094
Journal Article
Seminars in Oncology Nursing, ISSN 0749-2081, 11/2019, p. 150955
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2018, Volume 31, Issue 4, pp. 384 - 386
Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. The median overall survival... 
AML | Refractory | Relapse | Enasidenib | Ivosidenib | Quizartinib | Acute myeloid leukemia | Gemtuzumab ozogamicin | Gilteritinib | ADULT PATIENTS | PLUS CYTARABINE | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | Leukemia | Diseases
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2018, Volume 31, Issue 4, pp. 337 - 340
The FLT3 inhibitor midostaurin, the antibody-drug conjugate gemtuzumab ozogamicin, CPX-351 (liposomal daunorubicin and cytarabine), and the IDH2 inhibitor... 
AML | Histone deacetylase | Measurable residual disease | FLT3 | Gemtuzumab | Enasidenib | Ivosidenib | Midostaurin | IDH | Acute myeloid leukemia | MRD | Venetoclax | HEMATOLOGY | Medical colleges | Anthracyclines | Biological products | Drug approval | Leukemia
Journal Article
Nature, ISSN 0028-0836, 07/2018, Volume 559, Issue 7712, pp. 125 - 129
Somatic mutations in the isocitrate dehydrogenase 2 gene (IDH2) contribute to the pathogenesis of acute myeloid leukaemia (AML) through the production of the... 
LUNG-CANCER | CELLS | GEFITINIB | MUTANT IDH2 | MULTIDISCIPLINARY SCIENCES | ACUTE MYELOID-LEUKEMIA | DIFFERENTIATION | (R)-2-HYDROXYGLUTARATE | ENASIDENIB | Triazines - therapeutic use | Humans | Glutarates - blood | Isocitrate Dehydrogenase - antagonists & inhibitors | Aminopyridines - chemistry | Aminopyridines - therapeutic use | Enzyme Inhibitors - chemistry | HEK293 Cells | Protein Multimerization - genetics | Leukemia, Myeloid, Acute - drug therapy | Female | Triazines - chemistry | Mutant Proteins - antagonists & inhibitors | Allosteric Site - genetics | Triazines - pharmacology | Allosteric Site - drug effects | Mice, Inbred C57BL | Enzyme Inhibitors - pharmacology | Mutant Proteins - genetics | Models, Molecular | Isocitrate Dehydrogenase - genetics | Leukemia, Myeloid, Acute - blood | Enzyme Inhibitors - therapeutic use | Disease Progression | Isoleucine - genetics | Drug Resistance, Neoplasm - genetics | Animals | Aminopyridines - pharmacology | Alleles | Glutamine - genetics | Glutarates - metabolism | Mice | Mutation | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Drug Resistance, Neoplasm - drug effects | Leukemia, Myeloid, Acute - genetics | Antimitotic agents | Pharmaceutical research | Research | Drug resistance | Antineoplastic agents | Glutamine | Plasma | Pathogenesis | Leukemia | Lung cancer | Cloning | Neutrophils | Kinases | Cancer therapies | Patients | Proteins | Disease resistance | Allosteric properties | Inhibitors | Bone marrow | Dimers | Inhibition | Target acquisition | Isocitrate dehydrogenase | Isoleucine | Neutropenia | AG-120 | cancer metabolism | leukemia | AG-221 | metabolite | enasidenib | epigenetic | IDH1 | IDH2 | glioma | ivosidenib
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 12/2018, Volume 18, Issue 12, pp. 769 - 772
Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a... 
Beta-hydroxyglutarate | Acute myeloid leukemia | Isocitrate dehydrogenase | Enasidenib | Ivosidenib | ONCOLOGY | MUTANT IDH2 | ACUTE MYELOID-LEUKEMIA | PROGNOSTIC-SIGNIFICANCE | MUTATIONS | HEMATOLOGY
Journal Article
OncoImmunology, ISSN 2162-4011, 12/2018, Volume 7, Issue 12, p. e1528815
Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) or isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) are... 
ivosidenib | cancer-associated fibroblasts | HIF-1α | cytotoxic T lymphocytes | immunosurveillance | immunotherapy | IDH2 MUTATIONS | HIF-1 alpha | PROGNOSIS | GLIOMA | IMMUNOLOGY | CANCER | THERAPY | ONCOLOGY
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 11/2019, Volume 33, Issue 11, pp. e4658 - n/a
Isocitrate dehydrogenase (IDH) inhibitors comprise a novel class of anticancer drugs, which are approved to treat acute myeloid leukemia patients having... 
method validation | vorasidenib | enasidenib | mouse plasma | pharmacokinetics | ivosidenib | HPLC | CHEMISTRY, ANALYTICAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | PHARMACOLOGY & PHARMACY | Drug approval | High performance liquid chromatography | Methods | Index Medicus
Journal Article
Leukemia Research, ISSN 0145-2126, 10/2018, Volume 73, pp. 58 - 66
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 8/2019, Volume 75, Issue 8, pp. 1099 - 1108
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 01/2018, Volume 16, Issue 1, pp. 56 - e71
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 2019, Volume 12, pp. 303 - 308
Improvements in the last decade in understanding the molecular mechanisms underlying acute myeloid leukemia (AML) have emphasized that treatment regimens... 
AML | Refractory | IDH1 | Relapsed | Ivosidenib | refractory | CELLS | INHIBITION | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | MUTANT IDH1 | relapsed | ivosidenib | ACUTE MYELOID-LEUKEMIA | MUTATIONS | Studies | Dehydrogenases | Medical prognosis | Leukemia | Clinical trials | DNA methylation | Epigenetics | Lymphomas | Mutation | Gene expression | Deoxyribonucleic acid--DNA | Cancer
Journal Article
Blood and lymphatic cancer : targets and therapy, ISSN 1179-9889, 2019, Volume 9, pp. 19 - 32
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of... 
Enzymes | Dehydrogenases | Hematology | Leukemia | Genes | Systematic review | FDA approval | Metabolism | Epidemiology | Medical libraries | Data bases | Studies | Chemotherapy | Medical prognosis | Epigenetics | Mutation | acute myeloid leukemia | IDH1 | relapsed/refractory | ivosidenib | FT-2102 | venetoclax | isocitrate dehydrogenase 1
Journal Article